Private-equity firm KKR is close to acquiring a 50% stake in healthcare-technology company Cotiviti

  • KKR nears deal to buy stake in Cotiviti from Veritas Capital
  • Deal would value Cotiviti at about $11 billion
  • KKR could finalize agreement to buy 50% stake in Cotiviti in coming weeks

Private-equity firm Veritas Capital is close to a deal to sell a stake in Cotiviti to alternative-asset manager KKR in a deal that would value the healthcare-technology company at around $11 billion. KKR could finalize an agreement to buy a 50% stake in Cotiviti from Veritas as soon as in the coming weeks, people familiar with the matter said, assuming the talks don’t fall apart.

Factuality Level: 8
Factuality Justification: The article provides information about a potential deal between Veritas Capital and KKR to sell a stake in Cotiviti. The information is sourced from ‘people familiar with the matter,’ indicating that it is based on insider knowledge. However, since the deal has not been finalized yet, there is still a possibility that the talks could fall apart. Overall, the article provides factual information based on available sources, but the final outcome of the deal is not confirmed.
Noise Level: 3
Noise Justification: The article provides some relevant information about a potential deal between Veritas Capital and KKR to sell a stake in Cotiviti. However, it lacks in-depth analysis, evidence, and actionable insights. It is also quite short and does not provide much context or background information.
Financial Relevance: Yes
Financial Markets Impacted: Private-equity firms, healthcare-technology sector
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to a financial deal between private-equity firms, which is relevant to financial markets. There is no mention of an extreme event.
Private Companies: Cotiviti,Veritas Capital,KKR
Key People:

Reported publicly: www.wsj.com